StreetInsider.com News Articles

Lake Street Downgrades MDxHealth SA (MDXH) to Hold

Fri, 16 Oct 2026 07:30:08 -0400

Lake Street analyst Thomas Flaten downgraded MDxHealth SA (NASDAQ: MDXH) from Buy to Hold with a price target of $0.50.

For an analyst ratings summary and ratings history on MDxHealth SA click here. For more ratings news on MDxHealth SA click here.

Shares of MDxHealth SA closed at $0.60 yesterday.

Craig-Hallum Downgrades MDxHealth SA (MDXH) to Hold

Fri, 16 Oct 2026 07:14:28 -0400

Craig-Hallum analyst John Wilkin downgraded MDxHealth SA (NASDAQ: MDXH) from Buy to Hold.

For an analyst ratings summary and ratings history on MDxHealth SA click here. For more ratings news on MDxHealth SA click here.

Shares of MDxHealth SA closed at $0.60 yesterday.

Form 6-K MDxHealth SA For: Oct 16

Fri, 16 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261016/27195292.html

Form SCHEDULE 13D/A MDxHealth SA Filed by: Bleichroeder LP

Thu, 15 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261015/27193442.html

MdxHealth suspends 2026 guidance as Q3 revenue misses targets

Thu, 15 Oct 2026 16:00:49 -0400

MDxHealth SA (NASDAQ: MDXH) reported preliminary third quarter 2026 revenue from continuing operations of approximately $22.7 million, flat compared to $22.7 million in the same period a year earlier, and suspended its full-year 2026 revenue guidance of $110–$115 million, according to a press release issued October 15, 2026.

Tissue-based test volume, covering Confirm mdx and GPS mdx, fell 11% year-over-year to 11,232 in the quarter. Liquid-based Exo mdx test volume rose to 11,792 from 4,600 in the prior-year period, which reflects the company's September 2025 acquisition. Cash and cash equivalents stood at approximately $31.7 million as of September 30, 2026.

CEO Michael

MdxHealth suspends 2026 guidance as Q3 revenue misses targets

Thu, 15 Oct 2026 16:00:49 -0400

CEO Michael

MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance

Thu, 15 Oct 2026 16:00:00 -0400

IRVINE, CA – October 15, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full-year 2026 revenue guidance of $110–115 million.

The Company expects to report third quarter 2026 revenue from continuing operations of approximately $22.7 million, compared to $22.7 million in the third quarter of 2025 (re-presented to exclude Resolve mdx, which is reported as a discontinued operation). Third quarter tissue-based (Confirm mdx and GPS

MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance

Thu, 15 Oct 2026 16:00:00 -0400

Form 144 MDxHealth SA Filed by: Bleichroeder LP

Thu, 17 Sep 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260917/27076947.html

MDxHealth SA (MDXH) PT Lowered to $2 at BTIG

Fri, 21 Aug 2026 06:30:37 -0400

(Updated - August 21, 2026 6:30 AM EDT)

BTIG analyst Mark Massaro lowered the price target on MDxHealth SA (NASDAQ: MDXH) to $2.00 (from $4.00) while maintaining a Buy rating.

The analyst commented: "In this note, we update our MDXH model following Q2 results and we introduce our quarterly estimates for 2028. We thought the key update from the Q2 call was that MDXH executed an assignment for the benefit of creditors (ABC) that assigned all of its assets and liabilities related to its recently wound-down Resolve business. Importantly, the $10.4M recoupment claim that Medicare contractor Novitas was pursuing from MDx related

MDxHealth SA (MDXH) PT Lowered to $2 at BTIG

Fri, 21 Aug 2026 06:30:37 -0400

(Updated - August 21, 2026 6:30 AM EDT)

BTIG analyst Mark Massaro lowered the price target on MDxHealth SA (NASDAQ: MDXH) to $2.00 (from $4.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A MDxHealth SA Filed by: LYTTON LAURENCE W

Mon, 17 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26937996.html

Form SCHEDULE 13G/A MDxHealth SA Filed by: LYTTON LAURENCE W

Mon, 17 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26937996.html

Form 4 MDxHealth SA For: Aug 13 Filed by: Bednarski Eric

Mon, 17 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26937933.html

Form 4 MDxHealth SA For: Aug 13 Filed by: Bednarski Eric

Mon, 17 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26937933.html

Form SCHEDULE 13D MDxHealth SA Filed by: Bleichroeder LP

Fri, 14 Aug 2026 14:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26928882.html

Form SCHEDULE 13D MDxHealth SA Filed by: Bleichroeder LP

Fri, 14 Aug 2026 14:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26928882.html

These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started

Fri, 14 Aug 2026 13:13:02 -0400

DENVER, Aug. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ: NTHI), MDxHealth (NASDAQ: MDXH), and Capricor Therapeutics (NASDAQ: CAPR) are fundamentally driven healthcare stories, where clinical data, regulatory decisions, diagnostics adoption and cash runway determine whether today's enthusiasm can become a durable rerating, while Onfolio Holdings (NASDAQ:ONFO) is a structure-sensitive short squeeze.